Teva Pharmaceutical Industries Ltd. has announced positive data from the 3rd interim analysis of the pan-European PEARL study on AJOVY® (fremanezumab) for migraine prevention. The data reveals that almost 60% of patients achieved a ≥50% reduction in monthly migraine days, with sustained improvement in disability scores and acute medication use observed over 12 months. The treatment persistence rates were high, with 82.3% of patients remaining on treatment by month 12. The findings will be presented at the European Academy of Neurology Congress 2023.